Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Dirk Bier"'
Autor:
Roberta Cologni, Marcus Holschbach, Daniela Schneider, Dirk Bier, Annette Schulze, Carina Stegmayr, Heike Endepols, Johannes Ermert, Felix Neumaier, Bernd Neumaier
Publikováno v:
Molecules, Vol 29, Iss 16, p 3939 (2024)
Mutations of isocitrate dehydrogenase 1 (IDH1) are key biomarkers for glioma classification, but current methods for detection of mutated IDH1 (mIDH1) require invasive tissue sampling and cannot be used for longitudinal studies. Positron emission tom
Externí odkaz:
https://doaj.org/article/2d3f01074a8f4d80b35dfdde0eee8892
Autor:
Swen Humpert, Daniela Schneider, Markus Lang, Annette Schulze, Felix Neumaier, Marcus Holschbach, Dirk Bier, Bernd Neumaier
Publikováno v:
Molecules, Vol 29, Iss 5, p 1089 (2024)
Tozadenant (4-hydroxy-N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide) is a highly selective adenosine A2A receptor (A2AR) antagonist and a promising lead structure for the development of A2AR-selective positron emissi
Externí odkaz:
https://doaj.org/article/13659766cc3a4cf2ae1b446a114dad6e
Autor:
Jonas Goßen, Rui Pedro Ribeiro, Dirk Bier, Bernd Neumaier, Paolo Carloni, Alejandro Giorgetti, Giulia Rossetti
Identifying the correct chemotype of ligands targeting receptors (i.e., agonist or antagonist) is a challenge forin silicoscreening campaigns. Here we present an approach that identifies novel chemotype ligands by combining structural data with a ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::147f54540ce36cf9f991f3be367b0944
https://doi.org/10.1101/2023.03.31.535043
https://doi.org/10.1101/2023.03.31.535043
Publikováno v:
Pharmaceuticals, Vol 14, Iss 3, p 277 (2021)
Tracer development for positron emission tomography (PET) requires thorough evaluation of pharmacokinetics, metabolism, and dosimetry of candidate radioligands in preclinical animal studies. Since variations in pharmacokinetics and metabolism of a co
Externí odkaz:
https://doaj.org/article/7ca1f86d902d4a2585429746c68678a2
Autor:
Rejhana Kolašinac, Dirk Bier, Laura Schmitt, Andriy Yabluchanskiy, Bernd Neumaier, Rudolf Merkel, Agnes Csiszár
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 1, p 457 (2021)
Liposomes are highly biocompatible and versatile drug carriers with an increasing number of applications in the field of nuclear medicine and diagnostics. So far, only negatively charged liposomes with intercalated radiometals, e.g., 64Cu, 99mTc, hav
Externí odkaz:
https://doaj.org/article/f5ca91bade8c43289a62bb7ddfa23fe8
Autor:
Sibel Evcüman, Heike Endepols, Dirk Bier, Bernd Neumaier, Felix Neumaier, Annette Schulze, Chris Hoffmann, Boris D. Zlatopolskiy, Swen Humpert, Marcus H. Holschbach
Publikováno v:
ACS chemical neuroscience 12(18), 3335-3346 (2021). doi:10.1021/acschemneuro.1c00284
(2022). doi:10.1016/S0969-8051(22)00127-5
24th International Symposium on Radiopharmaceutical Sciences, iSRS 2022, Nantes, Germany, 2022-05-29-2022-06-03
(2022). doi:10.1016/S0969-8051(22)00127-5
24th International Symposium on Radiopharmaceutical Sciences, iSRS 2022, Nantes, Germany, 2022-05-29-2022-06-03
Objectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) originallydeveloped for the treatment of certain neurologic disorders like cognitive decline or schizophrenia. While it didnot reach clinical trials, ALX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bbf88ebcffe5bf92628ac6e6561a95e
https://doi.org/10.1021/acschemneuro.1c00284
https://doi.org/10.1021/acschemneuro.1c00284
Autor:
Daniela Schneider, Angela Oskamp, Marcus Holschbach, Bernd Neumaier, Andreas Bauer, Dirk Bier
Publikováno v:
Pharmaceuticals, Vol 12, Iss 2, p 57 (2019)
The prediction of in vivo clearance from in vitro metabolism models such as liver microsomes is an established procedure in drug discovery. The potentials and limitations of this approach have been extensively evaluated in the pharmaceutical sector;
Externí odkaz:
https://doaj.org/article/02ff415f50114e79a529e8148509d044
Autor:
Felix Neumaier, Annette Schulze, Birte Drewes, Wiebke Sihver, Dirk Bier, Franziska Wedekind, Marcus H. Holschbach, Bernd Neumaier, Andreas Bauer
Publikováno v:
Journal of radioanalytical and nuclear chemistry 326(3), 1691-1697 (2020). doi:10.1007/s10967-020-07465-2
5-Iodotubercidin is a prototype adenosine kinase (AK) inhibitor with potent anti-seizure activity in rodent epilepsy models. Using the chloramine-T method for radioiodination of tubercidin with 131I, we prepared no-carrier-added 5-[131I]iodotubercidi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63bb9cabbd3e0e4c3c651b8ca5adde62
https://doi.org/10.1007/s10967-020-07465-2
https://doi.org/10.1007/s10967-020-07465-2
Autor:
Dirk Bier, Marcus H. Holschbach, Daniela Schneider, Angela Oskamp, Andreas Bauer, Bernd Neumaier
Publikováno v:
Nuclear medicine and biology 82-83, 1-8 (2020). doi:10.1016/j.nucmedbio.2019.12.001
Introduction The suitability of novel positron emission tomography (PET) radioligands for quantitative in vivo imaging is affected by various physicochemical and pharmacological parameters. In this study, the combined effect of binding affinity, lipo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7fad11eb4f0b02dfe453fd675a2ae02
https://doi.org/10.1016/j.nucmedbio.2019.12.001
https://doi.org/10.1016/j.nucmedbio.2019.12.001
Autor:
Daniela Schneider, Annette Schulze, Swen Humpert, Marcus Holschbach, Dirk Bier, Bernd Neumaier
Publikováno v:
Nuclear Medicine and Biology. :S102-S103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b86a0ad717b64ce96491d8052f3afe9d
https://doi.org/10.1016/s0969-8051(22)00233-5
https://doi.org/10.1016/s0969-8051(22)00233-5